Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:RGEN
- CUSIP: 75991610
- Web: https://www.repligen.com/
- Market Cap: $1.54 billion
- Outstanding Shares: 37,356,000
- 50 Day Moving Avg: $41.71
- 200 Day Moving Avg: $36.92
- 52 Week Range: $26.16 - $46.81
Sales & Book Value:
- Trailing P/E Ratio: 80.39
- Foreward P/E Ratio: 55.77
- P/E Growth: 2.82
- Annual Revenue: $113.32 million
- Price / Sales: 13.60
- Book Value: $5.60 per share
- Price / Book: 7.37
- EBIDTA: $29.54 million
- Net Margins: 26.00%
- Return on Equity: 18.41%
- Return on Assets: 11.29%
- Debt-to-Equity Ratio: 0.51%
- Current Ratio: 11.87%
- Quick Ratio: 10.29%
- Average Volume: 346,438 shs.
- Beta: 1.3
- Short Ratio: 7.49
Frequently Asked Questions for Repligen (NASDAQ:RGEN)
What is Repligen's stock symbol?
Repligen trades on the NASDAQ under the ticker symbol "RGEN."
How were Repligen's earnings last quarter?
Repligen Co. (NASDAQ:RGEN) issued its earnings results on Thursday, August, 3rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.15 by $0.05. The firm had revenue of $32.40 million for the quarter, compared to analyst estimates of $31.72 million. Repligen had a return on equity of 18.41% and a net margin of 26.00%. The business's revenue was up 11.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.16 earnings per share. View Repligen's Earnings History.
When will Repligen make its next earnings announcement?
What guidance has Repligen issued on next quarter's earnings?
Repligen updated its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $0.57-0.62 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.56. The company issued revenue guidance of $138-144 million, compared to the consensus revenue estimate of $128.09 million.
Where is Repligen's stock going? Where will Repligen's stock price be in 2017?
4 equities research analysts have issued 12-month price targets for Repligen's stock. Their forecasts range from $37.00 to $47.00. On average, they anticipate Repligen's stock price to reach $41.00 in the next year. View Analyst Ratings for Repligen.
Who are some of Repligen's key competitors?
Some companies that are related to Repligen include Indivior PLC (INDV), Supernus Pharmaceuticals (SUPN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Aimmune Therapeutics (AIMT), Eagle Pharmaceuticals (EGRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), NOVAN INC (NOVN), Check-Cap (CHEK), CorMedix (CRMD), Advanced Accelerator Applications S.A. (AAAP), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).
Who are Repligen's key executives?
Repligen's management team includes the folowing people:
- Karen A. Dawes, Independent Chairperson of the Board
- Tony John Hunt, President, Chief Executive Officer, Director
- Jon K. Snodgres, Chief Financial Officer
- Howard Benjamin Ph.D., Vice President - Business Development
- Nicolas M. Barthelemy, Independent Director
- Glenn L. Cooper M.D., Independent Director
- John G. Cox, Independent Director
- Glenn P. Muir, Independent Director
- Thomas F. Ryan Jr., Independent Director
Who owns Repligen stock?
Repligen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.19%), TimesSquare Capital Management LLC (6.93%), Vanguard Group Inc. (5.82%), FMR LLC (3.91%), Conestoga Capital Advisors LLC (3.79%) and State Street Corp (3.14%). Company insiders that own Repligen stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.
Who sold Repligen stock? Who is selling Repligen stock?
Repligen's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Wells Fargo & Company MN, Dimensional Fund Advisors LP, Palisade Capital Management LLC NJ, Schwab Charles Investment Management Inc., Cornerstone Capital Management Holdings LLC., OxFORD Asset Management LLP and Bank of Montreal Can. Company insiders that have sold Repligen stock in the last year include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen.
Who bought Repligen stock? Who is buying Repligen stock?
Repligen's stock was purchased by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, William Blair Investment Management LLC, PointState Capital LP, Castleark Management LLC, Vanguard Group Inc., Stephens Investment Management Group LLC, BlackRock Inc. and Marshall Wace North America L.P.. View Insider Buying and Selling for Repligen.
How do I buy Repligen stock?
Shares of Repligen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Repligen's stock price today?
MarketBeat Community Rating for Repligen (NASDAQ RGEN)MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Repligen stock can currently be purchased for approximately $41.27.
Consensus Ratings for Repligen (NASDAQ:RGEN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Hold Ratings, 2 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||$41.00 (0.65% downside)|
Analysts' Ratings History for Repligen (NASDAQ:RGEN)
(Data available from 8/16/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|7/21/2017||William Blair||Initiated Coverage||Outperform -> Outperform||Low|
|6/28/2017||Jefferies Group LLC||Reiterated Rating||Hold||$33.00 -> $40.00||High|
|6/23/2017||Janney Montgomery Scott||Boost Price Target||$42.00 -> $47.00||High|
|4/21/2017||First Analysis||Reiterated Rating||Equal Weight||$40.00||Low|
|12/18/2016||Stephens||Set Price Target||Buy||$37.00||N/A|
|2/22/2016||Craig Hallum||Initiated Coverage||Buy||N/A|
Earnings History for Repligen (NASDAQ:RGEN)Earnings History by Quarter for Repligen (NASDAQ RGEN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/2/2017|| || || || || || || || |
|8/3/2017||Q2 2017||$0.15||$0.20||$31.72 million||$32.40 million||View||Listen|
|5/4/2017||3/31/2017||$0.13||$0.15||$29.28 million||$30.59 million||View||Listen|
|2/22/2017||Q416||$0.07||$0.08||$24.05 million||$25.60 million||View||Listen|
|11/3/2016||Q316||$0.08||$0.08||$24.39 million||$24.70 million||View||N/A|
|8/4/2016||Q216||$0.13||$0.16||$24.75 million||$29.20 million||View||N/A|
|5/5/2016||Q116||$0.10||$0.12||$22.54 million||$25.10 million||View||N/A|
|2/25/2016||Q415||$0.07||$0.07||$19.84 million||$21.40 million||View||Listen|
|11/5/2015||Q315||$0.08||$0.08||$20.50 million||$19.80 million||View||N/A|
|8/6/2015||Q215||$0.08||$0.11||$20.05 million||$21.50 million||View||N/A|
|5/7/2015||Q115||$0.07||$0.09||$18.20 million||$20.82 million||View||N/A|
|3/13/2015||Q414||$0.04||($0.01)||$14.70 million||$15.40 million||View||N/A|
|11/6/2014||Q314||$0.04||$0.04||$15.60 million||$15.30 million||View||N/A|
|8/11/2014||Q114||$0.06||$0.09||$14.90 million||$15.60 million||View||N/A|
|5/8/2014||Q1||$0.07||$0.13||$15.14 million||$16.33 million||View||Listen|
|3/6/2014||Q413||$0.14||$0.10||$15.88 million||$10.40 million||View||Listen|
|11/7/2013||Q313||$0.13||$0.18||$16.27 million||$18.80 million||View||Listen|
|8/1/2013||Q2 2013||$0.10||$0.14||$15.97 million||$17.50 million||View||Listen|
|5/2/2013||Q1 2013||$0.07||$12.82 million||$16.46 million||View||Listen|
|11/8/2012||Q312||$0.06||$8.63 million||$15.10 million||View||N/A|
Earnings Estimates for Repligen (NASDAQ:RGEN)
2017 EPS Consensus Estimate: $0.55
2018 EPS Consensus Estimate: $0.70
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Repligen (NASDAQ:RGEN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Repligen (NASDAQ:RGEN)
Insider Ownership Percentage: 1.50%Insider Trades by Quarter for Repligen (NASDAQ:RGEN)
Institutional Ownership Percentage: 99.49%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/21/2017||Karen A Dawes||Director||Sell||2,521||$34.12||$86,016.52|| |
|3/20/2017||Howard Benjamin||VP||Sell||12,216||$34.62||$422,917.92|| |
|3/20/2017||Thomas F Ryan Jr||Director||Sell||4,000||$34.83||$139,320.00|| |
|3/17/2017||Jon Snodgres||CFO||Sell||1,909||$34.91||$66,643.19|| |
|11/28/2016||Anthony Hunt||CEO||Sell||5,000||$33.12||$165,600.00|| |
|9/14/2016||Thomas F Ryan Jr||Director||Sell||2,700||$32.58||$87,966.00|| |
|6/30/2016||Thomas F Ryan Jr||Director||Sell||5,000||$26.60||$133,000.00|| |
|6/28/2016||Thomas F Ryan Jr||Director||Sell||10,000||$24.59||$245,900.00|| |
|5/11/2016||Howard Benjamin||VP||Sell||2,889||$26.72||$77,194.08|| |
|6/9/2015||Howard Benjamin||VP||Sell||35,000||$38.14||$1,334,900.00|| |
|5/11/2015||Walter C Herlihy||CEO||Sell||104,569||$37.94||$3,967,347.86|| |
|5/8/2015||Thomas F Ryan Jr||Director||Sell||20,000||$37.19||$743,800.00|| |
|3/23/2015||Walter C Herlihy||CEO||Sell||24,536||$31.78||$779,754.08|| |
|3/19/2015||James R Rusche||SVP||Sell||14,650||$33.30||$487,845.00|| |
|3/19/2015||Thomas F Ryan Jr||Director||Sell||10,000||$32.62||$326,200.00|| |
|3/19/2015||Walter C Herlihy||CEO||Sell||49,695||$33.08||$1,643,910.60|| |
|3/18/2015||Howard Benjamin||VP||Sell||15,795||$32.63||$515,390.85|| |
|11/19/2014||Walter C Herlihy||CEO||Sell||51,386||$23.43||$1,203,973.98|| |
|11/13/2014||Thomas F Ryan Jr||Director||Sell||10,000||$23.81||$238,100.00|| |
|11/11/2014||Howard Benjamin||VP||Sell||30,000||$23.56||$706,800.00|| |
|11/10/2014||Michael A Griffith||Director||Sell||23,342||$22.90||$534,531.80|| |
|8/13/2014||Howard Benjamin||VP||Sell||40,000||$20.34||$813,600.00|| |
|6/27/2014||Thomas F Ryan Jr||Director||Sell||10,000||$22.41||$224,100.00|| |
|6/24/2014||Thomas F Ryan Jr||Director||Sell||10,000||$21.78||$217,800.00|| |
|6/11/2014||Walter C Herlihy||CEO||Sell||60,335||$20.11||$1,213,336.85|| |
|6/9/2014||James R Rusche||SVP||Sell||30,000||$20.19||$605,700.00|| |
|6/6/2014||Daniel P Witt||SVP||Sell||47,709||$20.56||$980,897.04|| |
|4/15/2014||Daniel P Witt||SVP||Buy||10,000||$3.05||$30,500.00|| |
|8/8/2013||James R Rusche||SVP||Sell||30,000||$10.01||$300,300.00|| |
|6/21/2013||Karen A Dawes||Director||Buy||1,000||$7.70||$7,700.00|| |
|5/17/2013||Thomas F Ryan Jr||Director||Sell||21,000||$8.97||$188,370.00|| |
|5/15/2013||Thomas F Ryan Jr||Director||Sell||86,039||$9.01||$775,211.39|| |
|5/15/2013||Walter C Herlihy||CEO||Sell||40,000||$8.97||$358,800.00|| |
|9/21/2012||Glenn L Md Cooper||Director||Buy||10,000||$6.09||$60,900.00|| |
|8/16/2012||Michael A Griffith||Director||Buy||2,000||$4.88||$9,760.00|| |
Headline Trends for Repligen (NASDAQ:RGEN)
Latest Headlines for Repligen (NASDAQ:RGEN)
Repligen (RGEN) Chart for Wednesday, August, 16, 2017